ZYBERNO
Stock Report
Updated Jun 9, 2026

Biora Therapeutics, Inc. (BIORQ)

Healthcare • Over The Counter

$0.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
7.0/100
POOR BUSINESS
Biora Therapeutics, Inc. (BIORQ) scores 7/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-6,824.3%)
Return on Capital (Capital Efficiency):CRITICAL (-396.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Biora Therapeutics, Inc. (BIORQ) stock report — Zyberno Score 7/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, BIORQ generated -$49.00M in Owner Earnings. Capital was deployed as follows: $102.00K invested in capital expenditures. Reinvestment rate: 1.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.00
Market Cap:$365.29

Valuation Multiples (2)

P/S Ratio:0.00x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$1.23M
B. Profitability Assessment

Return Metrics (4)

ROA:-145.1%
Reinvestment Rate:1.0%
Fundamental Growth Rate (g):-3.9%

Margin Analysis (3)

Operating Margin Ttm:-6,824.3%
Net Margin Ttm:-3,535.8%
Ebitda Margin:-6,777.0%

TTM Performance (2)

Operating Margin Ttm:-6,824.3%
Net Margin Ttm:-3,535.8%

Yield Metrics (2)

Earnings Yield:-$8.20M
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-5.0%
Latest Earnings Filed:2024-11-14

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-50.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.05x
Quick Ratio:0.05x
Cash Ratio:0.02x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-9.17x
Times Interest Earned:-9.17

Capital Structure (4)

Working Capital:-114,564,000.00
Cash And Cash Equivalents:3,000,000.00
Long Term Debt:$1.05M
Net Debt:-$1.23M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $892.00K
Linear Growth: -50.0%
📊 Click to view full BIORQ Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$60.87M

Bottom Line Performance (3)

-$31.54M
Income Before Tax:-$93.46M
Ebitda Ttm:-60,451,000.00

Operating Expenses (5)

Operating Expenses:61,765,000.00
R And D Expense:26,437,000.00
Sga Expense:35,328,000.00
Income Tax Expense:-$62.00K
Interest Expense:7,324,000.00

Expense Ratios (3)

R And D To Revenue Percentage:82,615.6%
Sga To Revenue Percentage:110,400.0%
Ebitda Margin:-6,777.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$14.51M
Current Assets:$6.05M
Ppe Net:3,580,000.00
Goodwill:6,072,000.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:121,134,000.00
Current Liabilities:120,618,000.00
Long Term Debt:$1.05M
Short Term Debt:$717.00K

Equity & Capital (3)

Equity:-$106.63M
Retained Earnings:-$967.08M
Common Stock:300,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:6,916,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:1,281,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$48.90M-$49.00M

Investment Activities (2)

Investing Cash Flow:$3.01M
Capital Expenditures Ttm:102,000.00

Financing Activities (3)

Financing Cash Flow:$5.10M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:2,800,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:422,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-7.98
-$8.20
Earnings Per Share Ttm:-$8.63

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.24
Operating Cash Flow Per Share:-$13.28

Book Value & Capital (2)

Book Value Per Share:-$29.19
Cash Per Share:0.82

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.04x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:2,829.98
Cash Conversion Cycle:-4,827.98
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$49.00M

Damodaran Growth Analysis (2)

Reinvestment Rate:1.0%
Fundamental Growth Rate (g):-3.9%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:BIORQ
Company Name:Biora Therapeutics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:Over The Counter
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:3.65M
Shares Outstanding Basic:3.65M
Shares Outstanding Diluted:3.65M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-09 05:33:59 UTC
Data Timestamp:2026-06-09T05:33:59.552639
Scroll to Top